Dementias Completed Phase 3 Trials for Galantamine (DB00674)

Also known as: Dementia / Dementia NOS / Amentia

IndicationStatusPhase
DBCOND0060453 (Dementias)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02035982Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's DiseaseTreatment
NCT00216593Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyTreatment
NCT00216502A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseTreatment
NCT00236574A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentTreatment
NCT00236431A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentTreatment
NCT00253227A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseTreatment
NCT00253214Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release FormulationTreatment
NCT00253201A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseTreatment
NCT00253188A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseTreatment
NCT00338117Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's DiseaseTreatment